{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:47:31Z","timestamp":1769500051637,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":278,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Oxford PharmaGenesis\u2122"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jbo.2014.04.001","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T13:19:11Z","timestamp":1399641551000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective \u2013 prospective observational study \u2013 a cohort from 4 European countries"],"prefix":"10.1016","volume":"3","author":[{"given":"H.","family":"Hoefeler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garzon Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Atchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2014.04.001_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jbo.2014.04.001_bib2","first-page":"205","article-title":"Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention","volume":"2","author":"Lipton","year":"2004","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2014.04.001_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999\u20132007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.jbo.2014.04.001_bib5","doi-asserted-by":"crossref","first-page":"e18074","DOI":"10.1200\/jco.2010.28.15_suppl.e18074","article-title":"The incidence and prognostic significance of bone metastases and skeletal-related events in lung cancer patients: a population-based cohort study in Denmark","volume":"28","author":"Chia","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","article-title":"Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999\u20132006","volume":"131","author":"Sathiakumar","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jbo.2014.04.001_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jbo.2014.04.001_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.jbo.2014.04.001_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.jbo.2014.04.001_bib10","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib11","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jbo.2014.04.001_bib12","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manage Care"},{"key":"10.1016\/j.jbo.2014.04.001_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","article-title":"Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System","volume":"14","author":"Felix","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jbo.2014.04.001_bib15","series-title":"GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.jbo.2014.04.001_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12788\/j.suponc.0004","article-title":"Predicting life expectancy in patients with advanced incurable cancer: a review","volume":"11","author":"Krishnan","year":"2013","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.jbo.2014.04.001_bib18","unstructured":"Novartis Europharm Limited. Zometa (zoledronic acid): summary of product characteristics; 2012."},{"key":"10.1016\/j.jbo.2014.04.001_bib19","unstructured":"European Medicines Agency. Denosumab (XGEVA): summary of product characteristics; 2012."},{"key":"10.1016\/j.jbo.2014.04.001_bib20","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbo.2014.04.001_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2014.04.001_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2014.04.001_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2014.04.001_bib24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbo.2014.04.001_bib25","unstructured":"OncLive. Enzalutamide delays first skeletal-related event, improves pain and QOL in patients with metastatic prostate cancer. Available from: \u3008http:\/\/www.onclive.com\/publications\/obtn\/2012\/November-2012\/Enzalutamide-Delays-First-Skeletal-Related-Event-Improves-Pain-and-QOL-in-Patients-With-Metastatic-Prostate-Cancer\u3009 [accessed 11.03.14]."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137414000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137414000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:20Z","timestamp":1761941720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137414000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S2212137414000177"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2014.04.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective \u2013 prospective observational study \u2013 a cohort from 4 European countries","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2014.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier GmbH","name":"copyright","label":"Copyright"}]}}